ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc. (NDRA) filed this Current Report on Form 8-K on April 18, 2023. The filing relates to the submission of a Registration Statement on Form S-1/A (No. 333-271003) for an underwritten public offering of common stock and warrants. The report references preliminary unaudited estimated financial results for the fiscal quarter ended March 31, 2023, which are contained in an attached excerpt from the Prospectus (Exhibit 99.1).
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached Exhibit 99.1 (Excerpt from Prospectus) but are not detailed within the body of this 8-K document.
Material Changes
No material changes to financial results or operations are explicitly detailed in the text of this filing. The primary event reported is the filing of the Registration Statement for the capital raise.
Guidance, Outlook, and Risks
Management commentary, specific guidance, or detailed risk factors are not present in the text of this filing. The document notes that the information provided under Items 2.02 and 7.01 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Excerpt from Prospectus) for the specific preliminary unaudited estimated financial results for the quarter ended March 31, 2023.
- Verify the terms of the underwritten public offering of common stock and warrants referenced in the Form S-1/A.
- Confirm the status of the Registration Statement (No. 333-271003) with the SEC.